Astellas Pharma (OTCMKTS:ALPMY) Shares Gap Up – What’s Next?

Astellas Pharma Inc. (OTCMKTS:ALPMY)’s share price gapped up prior to trading on Friday . The stock had previously closed at $13.43, but opened at $14.21. Astellas Pharma shares last traded at $14.1385, with a volume of 12,726 shares changing hands.

Analyst Ratings Changes

ALPMY has been the subject of a number of recent analyst reports. Zacks Research cut shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research report on Monday. Smbc Nikko Sec. upgraded shares of Astellas Pharma to a “hold” rating in a report on Monday, February 16th. Finally, Jefferies Financial Group upgraded shares of Astellas Pharma from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 24th. One equities research analyst has rated the stock with a Strong Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold”.

Astellas Pharma Stock Performance

The company has a market capitalization of $25.68 billion, a price-to-earnings ratio of 13.21 and a beta of 0.08. The stock has a 50-day moving average price of $15.29 and a 200-day moving average price of $14.51. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.09 and a quick ratio of 0.84.

Astellas Pharma (OTCMKTS:ALPMY) last released its quarterly earnings data on Monday, April 27th. The company reported $0.33 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.19 by $0.14. Astellas Pharma had a return on equity of 24.19% and a net margin of 13.66%.The company had revenue of $3.38 billion during the quarter, compared to analysts’ expectations of $3.28 billion. As a group, analysts forecast that Astellas Pharma Inc. will post 1.29 earnings per share for the current year.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).